Donepezil Tied to Risk for Overactive Bladder

THURSDAY, Jan. 13, 2022 (HealthDay News) -- There is an increased risk for overactive bladder (OAB) with the cholinesterase inhibitor (ChEI) donepezil versus rivastigmine, according to a study published online Dec. 2 in the Journal of the American Geriatrics Society.
Prajakta P. Masurkar, from the University of Houston in Texas, and colleagues used Medicare claims data (Parts A, B, and D claims dataset from 2013 to 2015) to assess the risk for OAB with individual ChEIs in older adults with dementia. The analysis included 524,975 older adults with dementia who were incident users of ChEIs (80.72 percent used donepezil, 16.41 percent used rivastigmine, and 2.87 percent used galantamine).
The researchers found that overall, OAB diagnosis/antimuscarinic/mirabegron prescription was seen in 5.07 percent of the cohort within six months of ChEI prescription. Donepezil use increased the risk for OAB versus rivastigmine (adjusted hazard ratio, 1.13) when using propensity scores. There was no differential OAB risk between galantamine and rivastigmine.
"The study findings suggest the need to understand and manage medication-related morbidity in older adults with dementia," the authors write.
Abstract/Full Text (subscription or payment may be required)
Related Posts
Effectiveness of Ad26.COV2.S Vaccine Stable for Six Months
TUESDAY, March 22, 2022 (HealthDay News) -- The vaccine effectiveness (VE) of...
La obligatoriedad de las máscaras funcionó en las escuelas el otoño pasado, según un estudio de los CDC
MIÉRCOLES, 9 de marzo de 2022 (HealthDay News) -- Las órdenes de obligatoriedad...
How Easily Can Singing Spread COVID-19?
MONDAY, Nov. 29, 2021 (HealthDay News) -- Singing in a choir may be good for...
Flu Shot Recommended for All Children ≥6 Months, Early in Season
TUESDAY, Sept. 6, 2022 (HealthDay News) -- In a policy statement issued by the...
